Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,845 GBX | 0.00% |
|
-3.70% | +3.19% |
Jun. 24 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
Jun. 20 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+3.19% | 5.19B | |
+55.55% | 816B | |
+39.71% | 634B | |
-6.83% | 351B | |
+17.15% | 323B | |
+7.09% | 293B | |
+13.64% | 238B | |
+1.06% | 222B | |
+13.04% | 218B | |
+7.87% | 167B |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Transcript : Hikma Pharmaceuticals PLC, Xellia Pharmaceuticals ApS, Xellia Pharmaceuticals - M&A Call